Eisai Showcases Oncology Portfolio and Pipeline at ASCO 2024
May 23, 2024 – Clinical Trials, Drug Discovery – ASCO 2024, Eisai, oncology
23 May 2024 — Tokyo, Japan — Eisai Co announced today the presentation of research across multiple types of cancer from its oncology portfolio and pipeline during the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO24), which is taking place virtually and in-person in Chicago, Illinois, US, from 31 May to 4 June.
Notable data includes an oral presentation on biomarker analyses from the pivotal phase 3 CLEAR (Study 307)/KEYNOTE-581 trial (NCT02811861), which evaluated lenvatinib (LENVIMA) plus pembrolizumab (KEYTRUDA) versus sunitinib for the first-line treatment of patients with advanced renal cell carcinoma (Abstract #4504). An analysis of patterns of disease progression and subsequent therapy from this trial will also be presented in a poster presentation (Abstract #4524).
“At Eisai, we let the science drive us to new approaches that accelerate progress in oncology, while also remaining grounded in our human healthcare concept that reinforces our commitment to prioritise the needs of patients and families impacted by a cancer diagnosis,” said Dr Takashi Owa, chief scientific officer, senior vice president, Eisai Co. “With this in mind, we look forward to sharing research that provides further insight into the role of lenvatinib plus pembrolizumab as a first-line standard of care option in advanced renal cell carcinoma, as well as research that explores various modalities in our pipeline for the potential treatment of advanced diseases with the goal of improving patients’ lives.”
Other key research of note from Eisai’s pipeline include an oral presentation of phase 3 data from the JBCRG-M06/EMERALD study in Japan evaluating trastuzumab and pertuzumab in combination with Eisai’s eribulin mesylate or a taxane in patients with HER2-positive, locally advanced or metastatic breast cancer (NCT03264547; Abstract #1007). Additional pipeline research to be presented in poster sessions include an overview of a phase 2 study of BB-1701, an antibody drug conjugate targeting HER2, in previously treated patients with HER2-positive or HER2-low unresectable or metastatic breast cancer (NCT06188559; Abstract #TPS1122), findings from a phase 1b trial of tasurgratinib (development code: E7090) with or without endocrine therapies for patients with ER-positive, HER2−negative recurrent/metastatic breast cancer after receiving a CDK4/6 inhibitor (NCT04572295; Abstract #3103), as well as the dose-expansion part of a phase 1b global study of E7386 in combination with lenvatinib in patients with hepatocellular carcinoma and other solid tumours including endometrial cancer (NCT04008797; Abstract #TPS3169).
This release discusses investigational compounds and investigational uses for FDA-approved products. It is not intended to convey conclusions about efficacy and safety. There is no guarantee that any investigational compounds or investigational uses of FDA-approved products will successfully complete clinical development or gain FDA approval.
About Eisai
A leading global research and development-based pharmaceutical company headquartered in Japan.
Established in 1941, Eisai is a pharmaceutical company operating globally in terms of R&D, manufacturing and marketing, with a strong focus on prescription medicines. Visit: www.eisai.com/index.
